MedPath

FHI 360

FHI 360 logo
🇿🇲Zambia
Ownership
Private
Established
1971-01-01
Employees
1K
Market Cap
-
Website
http://www.fhi360.org

Clinical Trials

60

Active:1
Completed:46

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:4
Phase 2:3
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials

Not Applicable
29 (60.4%)
Phase 3
6 (12.5%)
Phase 4
5 (10.4%)
Phase 1
4 (8.3%)
Phase 2
3 (6.3%)
Early Phase 1
1 (2.1%)

The CATALYST Study

Terminated
Conditions
HIV Prevention
First Posted Date
2023-07-10
Last Posted Date
2025-03-13
Lead Sponsor
FHI 360
Target Recruit Count
6069
Registration Number
NCT05937698
Locations
🇰🇪

Chulaimbo sub-country hospital, Kisumu, Kenya

🇰🇪

Migosi Health, Kisumu, Kenya

🇰🇪

Likoni Sub-country hospital, Mombasa, Kenya

and more 25 locations

Eswatini Ring Study: Increasing PrEP Options for Women

Terminated
Conditions
HIV Prevention
First Posted Date
2023-06-05
Last Posted Date
2025-03-18
Lead Sponsor
FHI 360
Target Recruit Count
904
Registration Number
NCT05889533
Locations
🇸🇿

Dvokolwako Health Centre, Dvokolwako, Eswatini

🇸🇿

Manzini KP Community Centre, Manzini, Eswatini

🇸🇿

Matsapha Mobile Clinic, Matsapha, Eswatini

and more 5 locations

Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya

Not Applicable
Recruiting
Conditions
Anemia
Interventions
Drug: COCs
Device: LNG IUS
First Posted Date
2022-02-10
Last Posted Date
2025-04-20
Lead Sponsor
FHI 360
Target Recruit Count
600
Registration Number
NCT05233956
Locations
🇰🇪

Kangemi Health Center, Nairobi, Kenya

Casea S Contraceptive Implants (Casea S) Trial

Phase 1
Active, not recruiting
Conditions
Contraception
Interventions
Drug: 22.2 mg Etonogestrel (ENG)
Drug: 44.4 mg Etonogestrel (ENG)
First Posted Date
2022-01-03
Last Posted Date
2025-04-13
Lead Sponsor
FHI 360
Target Recruit Count
20
Registration Number
NCT05174884
Locations
🇩🇴

Clinica Profamilia, Santo Domingo, DN, Dominican Republic

REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

Not Applicable
Completed
Conditions
Child Mortality
Interventions
First Posted Date
2021-08-23
Last Posted Date
2025-03-04
Lead Sponsor
FHI 360
Target Recruit Count
767535
Registration Number
NCT05016895
Locations
🇨🇮

FHI 360, Abidjan, Côte D'Ivoire

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

News

Daré Bioscience and Theramex Partner to Develop Novel Biodegradable Contraceptive Implant

Daré Bioscience and Theramex have entered into a co-development agreement for Casea S, a first-in-category biodegradable contraceptive implant designed to last 18-24 months.

© Copyright 2025. All Rights Reserved by MedPath